enterprise Growth at RIL will come at a ‘cost’ The two new growth engines—telecom and retail—strive to take India’s largest corporate to a new peak while its traditional businesses continue to be a drag. By Anto T. Joseph
enterprise Hyderabad, the new vaccine capital of India Apart from Covaxin and Sputnik V, companies based in the city are also involved in developing or manufacturing several other Covid-19 vaccines. By Anto T. Joseph
enterprise Reprieve for DHFL’s FD holders as lenders go for ‘waterfall’ Lenders decide to pay FD depositors holding up to ₹2 lakh the full amount while other depositors will face the distribution mechanism. By Anto T. Joseph
enterprise How DHFL fits into Ajay Piramal’s plans The tycoon has finally won DHFL in a bruising bidding war. Here's Fortune India's earlier story explaining why the ailing home finance company is critical to his plans. By Anto T. Joseph
enterprise Bharat Biotech’s perception battle For BBIL’s founder Krishna Ella, the roll-out of a made-in-India vaccine, Covaxin, is peppered with challenges. Two recent deals with Brazilian and American firms have now buoyed him. By Anto T. Joseph
